MedTrace Logo

A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide

NCT05901649 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 504

Last updated 2026-05-08

No results posted yet for this study

Summary

The purpose of this study is to assess the real-world outcomes differences between apalutamide or enzalutamide plus androgen deprivation therapy (ADT) for the treatment of participants with metastatic hormone-sensitive prostate cancer (mHSPC).

Conditions

Interventions

DRUG

Apalutamide

No interventions will be administered as a part of this study. Participants will receive apalutamide as per their routine clinical practice.

DRUG

Enzalutamide

No interventions will be administered as a part of this study. Participants will receive enzalutamide as per their routine clinical practice.

Sponsors & Collaborators

  • Janssen-Cilag Ltd.

    lead INDUSTRY

Principal Investigators

  • Janssen-Cilag Ltd Clinical Trial · Janssen-Cilag Ltd.

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-05
Primary Completion
2026-06-05
Completion
2026-06-05

Countries

  • Austria
  • France
  • Germany
  • Greece
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05901649 on ClinicalTrials.gov